We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Navidea Inks Deal to to Sell Lymphoseek to Cardinal Health
Read MoreHide Full Article
Navidea Biopharmaceuticals, Inc (NAVB - Free Report) announced that it has entered into a definitive agreement to sell its Lymphoseek product to Cardinal Health (CAH - Free Report) .
Lymphoseek is used for lymphatic mapping, lymph node biopsy and the diagnosis of metastatic spread to lymph nodes for the staging of cancer in North America. In exchange, Navidea will receive $80 million on closing of the deal, as well as $230 million of contingent consideration based on certain milestones through 2026, of which $20.1 million is guaranteed over the next three years.
Cardinal Health will license a portion of the acquired intellectual property back to Navidea to allow it to develop and sell new immunodiagnostic and immunotherapeutic products for specific purposes in North America. Outside North America, Navidea will continue to produce and sell Lymphoseek under a different brand name.
The transaction is expected to close in the first quarter of 2017, subject to customary conditions, including an approval from Navidea’s shareholders, applicable regulatory approvals and the absence of a material adverse effect.
We note that Navidea entered into a loan agreement with Capital Royalty Partners II LP (CRG) on May 8, 2015. In Apr 2016, Navidea received a notice from CRG which claimed that due to certain events of default, all of Navidea’s remaining obligations under the loan agreement were due and payable.
Therefore, the agreement with Cardinal Health will enable Navidea to extinguish the CRG debt and focus on its development efforts.
Anika’s earnings estimates increased from $1.96 to $2.06 for 2016 and from $2.03 to $2.09 for 2017 over the last 30 days. The company posted a positive surprise in the four trailing quarters with an average beat of 33.14%. Its share price has gained 22.5% year to date.
Athersys’ loss estimates narrowed from 24 cents to 18 cents for 2016 and from 38 cents to 28 cents for 2017 over the last 60 days. The company posted a positive surprise in the four trailing quarters with an average beat of 110.52%. Its share price has gained 70% year to date.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Navidea Inks Deal to to Sell Lymphoseek to Cardinal Health
Navidea Biopharmaceuticals, Inc (NAVB - Free Report) announced that it has entered into a definitive agreement to sell its Lymphoseek product to Cardinal Health (CAH - Free Report) .
Lymphoseek is used for lymphatic mapping, lymph node biopsy and the diagnosis of metastatic spread to lymph nodes for the staging of cancer in North America. In exchange, Navidea will receive $80 million on closing of the deal, as well as $230 million of contingent consideration based on certain milestones through 2026, of which $20.1 million is guaranteed over the next three years.
Cardinal Health will license a portion of the acquired intellectual property back to Navidea to allow it to develop and sell new immunodiagnostic and immunotherapeutic products for specific purposes in North America. Outside North America, Navidea will continue to produce and sell Lymphoseek under a different brand name.
The transaction is expected to close in the first quarter of 2017, subject to customary conditions, including an approval from Navidea’s shareholders, applicable regulatory approvals and the absence of a material adverse effect.
We note that Navidea entered into a loan agreement with Capital Royalty Partners II LP (CRG) on May 8, 2015. In Apr 2016, Navidea received a notice from CRG which claimed that due to certain events of default, all of Navidea’s remaining obligations under the loan agreement were due and payable.
Therefore, the agreement with Cardinal Health will enable Navidea to extinguish the CRG debt and focus on its development efforts.
NAVIDEA BIOPHAR Price
NAVIDEA BIOPHAR Price | NAVIDEA BIOPHAR Quote
Zacks Rank & Key Picks
Investors looking for a couple of favorably placed stocks in the health care sector may consider Anika Therapeutics (ANIK - Free Report) and Athersys, Inc . Both of them sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Anika’s earnings estimates increased from $1.96 to $2.06 for 2016 and from $2.03 to $2.09 for 2017 over the last 30 days. The company posted a positive surprise in the four trailing quarters with an average beat of 33.14%. Its share price has gained 22.5% year to date.
Athersys’ loss estimates narrowed from 24 cents to 18 cents for 2016 and from 38 cents to 28 cents for 2017 over the last 60 days. The company posted a positive surprise in the four trailing quarters with an average beat of 110.52%. Its share price has gained 70% year to date.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>